Emphysema Treatment Market Report 2025

The emphysema treatment market size has grown strongly in recent years. It will grow from $5.15 billion in 2024 to $5.43 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to the smoking epidemic impact, advancements in medications, pulmonary rehabilitation programs, improved diagnostic tools, awareness and education.

The emphysema treatment market size is expected to see strong growth in the next few years. It will grow to $7.4 billion in 2029 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to aging population trends, customized treatment approaches, expanded access to therapies, focus on symptom management, and collaborative healthcare models. Major trends in the forecast period include the exploration of gene therapies, patient education and empowerment, integration of artificial intelligence (AI), increased accessibility to treatment, and long-acting medications development.

The increasing prevalence of chronic obstructive pulmonary disease (COPD) is anticipated to drive the growth of the emphysema treatment market in the future. COPD encompasses a range of disorders that lead to airflow obstruction and breathing difficulties, including emphysema and chronic bronchitis. Emphysema therapies are crucial for slowing the progression of COPD, as they aim to alleviate symptoms, restore lung function, and delay disease advancement. For example, reports from the Australian Institute of Health and Welfare (AIHW), an Australian agency, indicate that in 2022, approximately 638,000 individuals, or 2.5% of Australia’s population, were living with COPD. By 2023, COPD accounted for 3.6% of the overall disease burden, representing 50% of the total burden associated with respiratory conditions. Additionally, in 2022, COPD was the underlying cause of 7,691 deaths, which translates to 29.6 deaths per 100,000 people and constitutes 4% of all deaths in the country. Consequently, the rise in COPD cases is driving demand in the emphysema treatment market.

The rise in air pollution is projected to drive the growth of the emphysema treatment market in the coming years. Air pollution refers to the presence of harmful or undesirable substances in the air, which can negatively impact both the environment and human health. Increased levels of particulate matter and toxic gases can worsen respiratory conditions, including chronic obstructive pulmonary disease (COPD) such as emphysema. Higher exposure to air pollutants may lead to a surge in respiratory diseases, thereby increasing the demand for emphysema treatments. For instance, reports from the Environmental Protection Agency (EPA), a US federal agency, indicate that in 2023, around 66 million tons of pollutants were emitted into the atmosphere in the United States. As a result, the growing levels of air pollution are contributing to the expansion of the emphysema treatment market.

Prominent companies in the emphysema market are striving to gain a competitive advantage by developing minimally invasive procedures tailored for emphysema patients. Minimally invasive procedures involve medical interventions or surgical techniques that aim to cause minimal disruption to the body's normal structures. For example, in January 2022, Adena Health System, a healthcare company based in the United States, introduced Zephyr Valve surgery as a minimally invasive alternative to traditional lung volume reduction surgery for individuals experiencing lung hyperinflation, a common issue in emphysema and COPD. This innovative procedure involves the placement of small, one-way Zephyr Valves in the lungs' airways through a bronchoscope. These valves facilitate the release of trapped air, preventing further accumulation and enabling healthier lung areas to expand, thereby improving breathing.

Leading companies in the emphysema market are also focusing on the development of innovative products, such as inhalation aerosols, to establish a competitive edge. Inhalation aerosols are pharmaceutical formulations dispensed as a fine mist or spray of liquid medication suspended in a propellant or propellant mixture. For instance, in July 2023, Viatris Inc., a U.S.-based pharmaceutical company, in collaboration with Kindeva Drug Delivery L.P., a U.S.-based pharmaceutical contract development and manufacturing organization (CDMO), launched Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol. This marks the first FDA-approved generic version of AstraZeneca's Symbicort, catering to patients managing asthma, chronic obstructive pulmonary disease (COPD), and emphysema. Breyna, available in various dosage strengths, signifies a crucial advancement in providing accessible and cost-effective treatment options for individuals facing respiratory challenges.

In March 2023, UC Davis Health, an academic health institution based in the United States, entered into a collaboration with Propeller Health to offer individualized treatment for chronic obstructive pulmonary disease (COPD) and asthma through remote patient monitoring technology. This partnership allows UC Davis Health to provide eligible patients with Propeller Health's remote patient monitoring (RPM) service, delivering personalized therapy for high-risk COPD and asthma patients using sensors, a smartphone application, and a website. Propeller Health, a U.S.-based mobile platform company, provides sensors, mobile apps, analytics, and services to assist in respiratory health management.

Major companies operating in the emphysema treatment market include AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Boehringer Ingelheim GmbH, Mylan N.V., Pfizer Inc., Orion Oyj, Verona Pharma PLC, Pulmonx Corporation, Emphasys Medical Inc., Halozyme Therapeutics Inc., Mariposa Health Limited, Uptake Technologies Inc., Respinova Ltd, Gala Therapeutics Inc., Pulmatrix Inc., Broncus Medical Inc., Holaira Inc., PneumRx Inc., Spiration Inc., Aeris Therapeutics Inc., CSA Medical Inc., Olympus Corporation.

North America was the largest region in the emphysema treatment market in 2024. The regions covered in the emphysema treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the emphysema treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Emphysema treatment refers to medication for chronic obstructive pulmonary disease (COPD), a condition that leads to damage in the air sacs of the lungs, resulting in difficulty breathing. Treatments for emphysema aim to manage symptoms and slow the progression of the disease.

The primary treatments for emphysema include smoking cessation, bronchodilators, steroids, leukotriene modifiers, supplemental oxygen, antibiotics, gene therapy, surgery transplant, and others. Smoking cessation involves the cessation of smoking to reduce the risk of cancer and other significant health issues. This process helps minimize cravings and withdrawal symptoms while preventing nicotine binding. These treatments are available through various distribution channels, including online providers, drug stores, retail pharmacies, and hospital pharmacies. They are utilized by various end-users such as clinics, surgical centers, and others.

The emphysema treatment market research report is one of a series of new reports that provides emphysema treatment market statistics, including emphysema treatment industry global market size, regional shares, competitors with an emphysema treatment market share, detailed emphysema treatment market segments, market trends and opportunities, and any further data you may need to thrive in the emphysema treatment industry. This emphysema treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The emphysema treatment market includes revenues earned by entities by providing medical services such as bronchodilator medications, anti-inflammatory medication, oxygen therapy, lifestyle change consultation, and interventional therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.